References
- Gordon S, Martinez FO. Alternative activation of macrophages: mechanism and functions. Immunity. 2010;32:593–604.
- Jaguin M, Houlbert N, Fardel O, Lecureur V. Polarization profiles of human M-CSF-generated macrophages and comparison of M1-markers in classically activated macrophages from GM-CSF and M-CSF origin. Cell Immunol. 2013;281:51–61.
- Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 2008;8:958–969.
- Badylak SF, Valentin JE, Ravindra AK, et al. Macrophage phenotype as a determinant of biologic scaffold remodeling. Tissue Eng Part A. 2008;14:1835–1842.
- Martinez FO, Helming L, Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol. 2009;27:451–483.
- Murphy BS, Bush HM, Sundareshan V, et al. Characterization of macrophage activation states in patients with cystic fibrosis. J Cyst Fibros. 2010;9:314–322.
- Higashi-Kuwata N, Jinnin M, Makino T, et al. Characterization of monocyte/macrophage subsets in the skin and peripheral blood derived from patients with systemic sclerosis. Arthritis Res Ther. 2010;12:R128.
- Mathai SK, Gulati M, Peng X, et al. Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype. Lab Invest. 2010;90:812–823.
- Gibbons MA, MacKinnon AC, Ramachandran P, et al. Ly6Chi monocytes direct alternatively activated profibrotic macrophage regulation of lung fibrosis. Am J Respir Crit Care Med. 2011;184:569–581.
- Wang J, Jiang Z-P, Su N, et al. The role of peritoneal alternatively activated macrophages in the process of peritoneal fibrosis related to peritoneal dialysis. Int J Mol Sci. 2013;14:10369–10382.
- Hu W, Jiang Z, Zhang Y, et al. Characterization of infiltrating macrophages in high glucose-induced peritoneal fibrosis in rats. Mol Med Rep. 2012;6:93–99.
- Su N, Li Y, Wang J, et al. Role of MAPK signal pathways in differentiation process of M2 macrophages induced by high-ambient glucose and TGF-beta1. J Recept Signal Transduct Res. 2015;35: 396–401.
- Hata A, Chen YG. TGF-beta Signaling from Receptors to Smads. Cold Spring Harb Perspect Biol. 2016;8:a022061.
- Zhang Q, Lu Y, Ma Z, et al. A novel formula from mulberry leaf ameliorates diabetic nephropathy in rats via inhibiting the TGF-beta1 pathway. Food Funct. 2015;6:3307–3315.
- Sakai N, Wada T, Furuichi K, et al. Involvement of extracellular signal-regulated kinase and p38 in human diabetic nephropathy. Am J Kidney Dis. 2005;45:54–65.
- Massague J. How cells read TGF-beta signals. Nat Rev Mol Cell Biol. 2000;1:169–178.
- Hayashida T, Decaestecker M, Schnaper HW. Cross-talk between ERK MAP kinase and Smad signaling pathways enhances TGF-beta-dependent responses in human mesangial cells. FASEB J. 2003;17:1576–1578.
- Osaki LH, Gama P. MAPKs and signal transduction in the control of gastrointestinal epithelial cell proliferation and differentiation. IJMS. 2013;14:10143–10161.
- de Caestecker MP, Parks WT, Frank CJ, et al. Smad2 transduces common signals from receptor serine-threonine and tyrosine kinases. Genes Dev. 1998;12:1587–1592.
- Funaba M, Zimmerman CM, Mathews LS. Modulation of Smad2-mediated signaling by extracellular signal-regulated kinase. J Biol Chem. 2002;277:41361–41368.
- Kretzschmar M, Doody J, Timokhina I, et al. A mechanism of repression of TGFbeta/Smad signaling by oncogenic Ras. Genes Dev. 1999;13:804–816.